09/21/23 10:00 AMNasdaq : BMRN conferencesBioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) MeetingBioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on VOXZOGO ® in children with achondroplasia will be presented at the...RHEA-AIneutral
09/15/23 9:29 AMNasdaq : BMRN BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with AchondroplasiaU.S. Food and Drug Administration PDUFA Target Action Date for Supplemental New Drug Application for VOXZOGO for Children Under 5 is Oct. 21, 2023. The U.S. Food and Drug Administration has also set a PDUFA Target Action Date of Oct. 21, 2023, for the company's Supplemental New Drug Application for VOXZOGO to expand treatment in the United States to include...RHEA-AIneutral
09/11/23 8:30 AMNasdaq : BMRN conferencesBioMarin to Present Innovative Pipeline at R&D Day on September 12th in New YorkBioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, will update the investor community on the company's research and development portfolio, including early-stage product candidates and new indication opportunities with VOXZOGO and...RHEA-AIneutral
09/06/23 8:30 AMNasdaq : BMRN conferencesBioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12thBioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. Professor Johnny Mahlangu, MBBCh, MMed, FCPath– Director Haemophilia Comprehensive Care, Charlotte Maxeke Johannesburg...RHEA-AIneutral
09/05/23 8:30 AMNasdaq : BMRN conferencesBioMarin to Participate in Three Upcoming Investor ConferencesBioMarin Pharmaceutical Inc. today announced that company management will present at...RHEA-AIneutral
08/30/23 4:05 PMNasdaq : BMRN BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in EuropeBioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that an individual in Germany with severe hemophilia A was treated with ROCTAVIAN ®,...RHEA-AIneutral
07/31/23 4:03 PMNasdaq : BMRN earningsBioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-dateVOXZOGO ® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023 U.S. Approval of ROCTAVIAN™ Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in...RHEA-AIneutral
07/12/23 9:27 AMNasdaq : BMRN conferencesearningsBioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ETBioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31, at 4:30 p.m. ET to discuss second-quarter 2023 financial results and provide a general business update. Dial-in Number U.S./ Canada...RHEA-AIneutral
06/29/23 2:34 PMNasdaq : BMRN fda approvalU.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia ABioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the United States Food and Drug Administration approved ROCTAVIAN™ gene therapy for the treatment of adults with severe hemophilia A without antibodies to...RHEA-AIneutral
06/22/23 8:00 AMNasdaq : BMRN conferencesclinical trialBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 CongressBioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, today announced it will present new data from the ROCTAVIAN™ gene therapy clinical trial program. These data will be shared this week in four oral presentations and two posters at the 31st...RHEA-AIneutral